- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02051673
Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)
July 15, 2022 updated by: Talaris Therapeutics Inc.
Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx)
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Detailed Description
Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx) and living donor kidney transplant.
Study Type
Expanded Access
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient must be between the ages of 18 and 65 years and meet the institution's criteria for renal transplantation for end-organ failure
- Patient is receiving first renal transplant
- Patient is receiving a renal transplant only
- The crossmatch is negative between donor and recipient
- Women who are of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours of initiating total body irradiation (TBI) and agree to use reliable contraception for 1 year following transplant
- Potential donors who are women of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours prior to receiving Granulocyte colony-stimulating factor (G-CSF)
- No evidence of donor-specific antibody presently or historically
Exclusion Criteria:
- Clinically active bacterial, fungal, viral or parasitic infection
- Pregnancy
- Clinical or serologic evidence of viral infection which would preclude the recipient from receiving a kidney transplant
- Previous radiation therapy at a dose which would preclude TBI
- Positive crossmatch between donor and recipient
- Evidence for immunologic memory against donor
- BMI >35 or <18
- Re-transplant
- Positive serologies for hepatitis B virus (HBV), hepatitis C virus (HCV), HIV
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
January 29, 2014
First Submitted That Met QC Criteria
January 29, 2014
First Posted (ESTIMATE)
January 31, 2014
Study Record Updates
Last Update Posted (ACTUAL)
July 18, 2022
Last Update Submitted That Met QC Criteria
July 15, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICT-7392-Compassionate Use
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Failure
-
University of Sao Paulo General HospitalUnknownRenal Transplant Rejection | Graft Failure | Transplant; Failure, Kidney | Chronic Renal Failure (CRF)Brazil
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Canada
-
Washington University School of MedicineCompletedAcute Renal Failure | Chronic Renal FailureUnited States
-
University Hospital, Clermont-FerrandRecruitingAcute Kidney Injury | Transient Acute Renal Failure | Persistent Acute Renal FailureFrance
-
University Hospital, GhentCompletedAcute Renal Failure | Chronic Renal FailureBelgium
-
The University of Hong KongHospital Authority, Hong KongCompletedEnd-stage Renal Failure (ESRF)Hong Kong
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
-
PfizerCompletedChronic Renal Failure Requiring HemodialysisUnited States, Puerto Rico
Clinical Trials on Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion
-
Talaris Therapeutics Inc.Duke UniversityWithdrawnAnemia, Sickle Cell | Thalassemia | Beta-Thalassemia | Bone Marrow Failure Syndromes | Diamond-Blackfan Anemia | Alpha-Thalassemia | Complex and Transfusion-dependent HemoglobinopathiesUnited States
-
Suzanne T. IldstadCompleted
-
Talaris Therapeutics Inc.Duke UniversityNo longer availableMetachromatic LeukodystrophyUnited States
-
Talaris Therapeutics Inc.Duke UniversityNo longer availableMetachromatic LeukodystrophyUnited States
-
Talaris Therapeutics Inc.Duke University; University of Florida; St. Christopher's Hospital for Children; Hahnemann University Hospital and other collaboratorsCompletedSickle Cell DiseaseUnited States
-
Talaris Therapeutics Inc.WithdrawnMultiple Sclerosis
-
Talaris Therapeutics Inc.Northwestern UniversityActive, not recruitingRenal FailureUnited States
-
Talaris Therapeutics Inc.Northwestern University; Duke University; Regenerex, LLCTerminatedKidney FailureUnited States
-
University of PittsburghRecruitingLysosomal Storage Diseases | Leukodystrophy | Niemann-Pick Diseases | Batten Disease | Gaucher Disease | Krabbe Disease | Alpha-Mannosidosis | Osteopetrosis | Tay-Sachs Disease | Pelizaeus-Merzbacher Disease | Sandhoff Disease | GM1 Gangliosidoses | MPS I | MPS II | Vanishing White Matter Disease | Multiple Sulfatase Deficiency... and other conditionsUnited States
-
Stanford UniversityNorthwestern University; California Institute for Regenerative Medicine (CIRM)RecruitingLiving Donor Kidney TransplantationUnited States